Hereditary ataxia is complex, with significant clinical overlap among multiple subtypes. In this test-specific episode of the "Answers From the Lab" podcast, Angela Pickart, M.S., CGC, and Emily Lauer, M.S., CGC, explain how Mayo Clinic Laboratories' ATAXP panel provides cost-effective molecular diagnosis to guide management of this movement disorder.

"This panel uses next-generation sequencing to detect variants in 198 genes, which have been carefully vetted by experts," Lauer says. "Ensuring that the genes on a large testing panel are truly associated with disease assists in minimizing detection of variants of uncertain significance."

The panel can be especially helpful if an individual's clinical and family history isn't consistent with spinocerebellar ataxia or Friedreich ataxia. Mayo Clinic Laboratories also offers testing that targets those forms of ataxia.

"Understanding the underlying cause of an individual's genetic condition can help with prognosis, clinical management and family screening," Pickart says. "Once nongenetic etiologies have been excluded, it is reasonable to consider genetic testing for any individual to assess for hereditary ataxia."

Listen to learn more about Mayo Clinic Laboratories' hereditary ataxia panel.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

ATAXP   | Inherited Ataxia Gene Panel, Varies

Useful information

Establishing a molecular diagnosis for patients with ataxia.

Identifying variants within genes known to be associated with ataxia, allowing for predictive testing of at-risk family members.

Specimen requirements

Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

Specimen Type: Whole blood

Container/Tube: Lavender top (EDTA) or yellow top (ACD)

Acceptable: Any anticoagulant

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.

Specimen Stability Information: Ambient (preferred)/Refrigerated

Performance information

• Analytic time: 28 - 42 days
• Day(s) and time(s) performed: Varies

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less